Exhibit 99.1

 

LOGO      InfuSystem Holdings, Inc.
     31700 Research Park Drive
     Madison Heights, MI 48071
     248-291-1210

 

CONTACT:    Joe Dorame, Joe Diaz & Robert Blum
   Lytham Partners, LLC
   602-889-9700

INFUSYSTEM HOLDINGS, INC. REPORTS

SECOND QUARTER 2016 FINANCIAL RESULTS

Second Quarter 2016 Net Revenues UP 11%

MADISON HEIGHTS, MICHIGAN, August 10, 2016 — InfuSystem Holdings, Inc. (NYSE MKT: INFU) (“InfuSystem” or the “Company”), a leading national provider of infusion pumps and related services for the healthcare industry in the United States, today reported financial results for the quarter ended June 30, 2016.

Highlights for the second quarter of 2016 included:

 

    Net Revenues totaled $19.1 million, an increase of 11% versus second quarter 2015 net revenues of $17.2 million.

 

    Net Collected Revenues increased 12% over last year’s comparable quarter.

 

    Net Collected Rental Revenues increased 11% over last year’s comparable quarter.

 

    Product sales increased 21% to $1.9 million over last year’s comparable quarter.

 

    Bad debt decreased 7% for the quarter compared to the prior year period, as a result of the Company’s increased focus on new payor contracts and patient collections.

 

    Net Income of $0.7 million, or diluted EPS of $0.03, compared to second quarter 2015 net income of $0.8 million or diluted EPS of $0.03.

 

    AEBITDA increased 10% to $4.3 million and AEBITDA margin was 22.8%.

 

    The Company purchased $2.7 million in the second quarter and $5.8 million YTD of medical equipment in rental service expected to be deployed during the second half of the year.

 

Page 1 of 10


Management Discussion

Eric K. Steen, chief executive officer of InfuSystem, said, “In the face of sweeping changes by the federal government to the Medicare patient ambulatory pump reimbursement process during the second quarter, which has been described in detail in our SEC filings, our team achieved double-digit growth with a 10% increase in our net rental revenues driven by a 24% increase in our direct rental business. During the first half of the year we added 116 new customers and we deployed a record of approximately 2,500 infusion pumps into the oncology market; setting the stage for strong revenue growth in the second half of 2016. I am pleased with the dedication, hard work and focus of all our employees to quickly adapt and work with our customers to navigate through the new CMS reimbursement changes.”

Mr. Steen continued, “We continued to expand the rollout of our new EXPRESS system, as we now have approximately 1,375 medical facilities converted to our new connectivity system. InfuSystem EXPRESS delivers significant operating efficiencies to our customers by eliminating duplicate data entry and errors associated with human input. Also, we are directly integrated to the electronic medical record system with 114 facilities utilizing our InfuBus™ integration engine.”

Mr. Steen concluded, “It is important to note that upon placement of an infusion pump with new large hospital customers, it can take up to 6 months before we start to recognize revenue from that pump. Given the record number of pumps that have been deployed in the first half of the year and the number of new customers added to our base, we expect that our gross margins will be positively impacted as deployments slow from recent record levels and we recognize the additional revenue. Our goal is to continue to build off this positive momentum, deliver meaningful IT solutions, diversify our revenue stream and finish the year with solid top- and bottom-line growth.”

Second Quarter Results

Net revenues in the second quarter of 2016 were $19.1 million, an increase of $1.9 million, or 11%, from $17.2 million in the second quarter of 2015. Net rental revenues increased 10% to $17.2 million; net revenues from product sales, mainly disposables, increased 21% to $1.9 million from the second quarter of 2015. The increase in net revenues can be attributed to greater rental volume with new and existing sites of therapy, partially offset by a higher mix of Medicaid and patient payors in our rental business, which generally have lower collection rates than commercial payors.

 

Page 2 of 10


The Company is focused on net rental revenues less bad debt (“Net Collected Rental Revenues”) versus prior year. Net Collected Rental Revenues increased 11% to $16.1 million versus $14.5 million in the comparable quarter of 2015. Bad debt as a percentage of net revenues decreased to 6% compared to 7% for the same prior year period.

Net income in the second quarter was $0.7 million, equal to $0.03 per diluted share, compared to net income of $0.8 million, or $0.03 per diluted share, in the same prior year period. Adjusted net income, adding back interest expense and other income and expenses was $0.8 million, or $0.04 per diluted share, compared to $1.1 million, or $0.05 per diluted share, in the same prior year period.

Gross profit for the three months ended June 30, 2016 was $12.1 million, an increase of $0.2 million, or 2%, from $11.9 million in the second quarter of 2015. It represented 63% of net revenues in the second quarter compared to 69% in the prior year period. The decrease in gross profit as a percentage of net revenues for the period is mainly due to the increase in cost of revenues – product and supply costs, including $0.5 million for additional depreciation on newly purchased pumps.

During the three months ended June 30, 2016, general and administrative (“G&A”) expenses were $6.4 million, an increase of $0.4 million, or 7%, compared to $6.0 million for the same prior year period. The increase in G&A expenses versus the same prior year period was mainly attributable to increases in spending on IT of $0.9 million, offset by decreases in stock compensation expense and professional fees of $0.5 million.

Selling and marketing expenses for the 2016 second quarter were $2.3 million, a decrease of $0.4 million, or 14%, compared to $2.7 million in the second quarter of 2015. Other expenses for the second quarter of 2016 were $0.3 million compared to $0.4 million for the same prior year period. This is a direct result of the lower interest rates associated with the Company’s new credit facility.

 

Page 3 of 10


Adjusted EBITDA was $4.3 million, an increase of 10% for the second quarter of 2016 compared to $3.9 million for the same period in 2015. The Company utilizes Adjusted Net Income and Adjusted EBITDA as a means to measure its operating performance. A reconciliation from GAAP operating measures to Adjusted Net Income and Adjusted EBITDA, both non-GAAP measures, can be found in the appendix. Adjustments during the quarter were for severance related to our sales force management restructure and for costs associated in identifying and investigating strategic alternatives.

Financial Condition

Cash provided by operating activities for the six months ended June 30, 2016 was $1.9 million compared to $3.8 million for the six months ended June 30, 2015. This decrease is mainly due to increases in accounts receivable and decreases in other current liabilities.

Cash used in investing activities was $5.4 million for the six months ended June 30, 2016, compared to cash used of $11.4 million for the six months ended June 30, 2015. The decrease in cash used was due primarily to the $3.8 million payment for the Ciscura acquisition made during the six months ended June 30, 2015. The Company has spent approximately $2.5 million on IT capital projects for the year. There was also a decrease in spending on non-pump assets of $0.1 million and a $0.9 million increase in cash used to purchase medical equipment.

As of June 30, 2016, the Company maintained cash and cash equivalents of $0.8 million and $3.3 million of net availability under the Revolver compared to $0.8 million and $9.9 million, respectively, at December 31, 2015.

Guidance

The Company maintains, for 2016, guidance of high single digit net collected revenue growth.

Conference Call

The Company will conduct a conference call for investors on Wednesday, August 10, 2016 at 11:00 a.m. Eastern Time to discuss second quarter performance and results. Eric K. Steen, chief executive officer, Jan Skonieczny, chief operating officer, Chris Downs, interim chief financial officer, Trent Smith, chief accounting officer and the Company’s outgoing chief financial officer, Jonathan P. Foster will discuss the Company’s financial performance and answer questions from the financial community. To participate in this call, please dial in toll-free (800) 446-1671 and use the confirmation number 43085578. This press release will be available on most financial websites. Additionally, a web replay will be available on the Company’s website for 30 days.

 

Page 4 of 10


Non-GAAP Measures

This press release contains information prepared in conformity with GAAP as well as non-GAAP information. It is management’s intent to provide non-GAAP financial information in order to enhance readers’ understanding of its consolidated financial information as prepared in accordance with GAAP. This non-GAAP information should be considered by the reader in addition to, but not instead of, the financial statements prepared in accordance with GAAP. Each non-GAAP financial measure and the corresponding GAAP financial measures are presented so as to not imply that more emphasis should be placed on the non-GAAP measure. The non-GAAP financial information presented may be determined or calculated differently by other companies. Additional information about non-GAAP financial measures and a reconciliation of those measures to the most directly comparable GAAP measures are included later in this release.

About InfuSystem Holdings, Inc.

InfuSystem Holdings, Inc. is a leading provider of infusion pumps and related services to hospitals, oncology practices and other alternate site healthcare providers. Headquartered in Madison Heights, Michigan, the Company delivers local, field-based customer support and also operates Centers of Excellence in Michigan, Kansas, California, Texas, Georgia and Ontario, Canada. The Company’s stock is traded on the NYSE MKT under the symbol INFU.

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “strategy,” “future,” “likely,” variations of such words, and other similar expressions, as they relate to the Company, are intended to identify forward-looking statements. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. In connection with the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, the Company is identifying certain factors that could cause actual results to differ, perhaps materially, from those indicated by these forward-looking statements. Those factors, risks and uncertainties include, but are not limited to, potential changes in overall healthcare reimbursement, including CMS competitive bidding, sequestration, concentration of customers, increased focus on early detection of cancer, competitive treatments, dependency on Medicare Supplier Number, availability of

 

Page 5 of 10


chemotherapy drugs, global financial conditions, changes and enforcement of state and federal laws, natural forces, competition, dependency on suppliers, risks in acquisitions & joint ventures, U.S. Healthcare Reform, relationships with healthcare professionals and organizations, technological changes related to infusion therapy, dependency on websites and intellectual property, the ability of the Company to successfully integrate acquired businesses, dependency on key personnel, dependency on banking relations and covenants, and other risks associated with our common stock, as well as any litigation to which the Company may be involved in from time to time; and other risk factors as discussed in the Company’s annual report on Form 10-K for the year ended December 31, 2015 and in other filings made by the Company from time to time with the Securities and Exchange Commission, including our Form 10-Q for the second quarter of 2016. Our annual report on Form 10-K is available on the SEC’s EDGAR website at www.sec.gov, and a copy may also be obtained by contacting the Company. All forward-looking statements made in this press release speak only as of the date hereof. We do not intend, and do not undertake any obligation, to update any forward-looking statements to reflect future events or circumstances after the date of such statements.

Additional information about InfuSystem Holdings, Inc. is available at www.infusystem.com.

FINANCIAL TABLES FOLLOW

 

Page 6 of 10


INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

 

     As of  
     June 30,     December 31,  

(in thousands, except share data)

   2016     2015  
     (Unaudited)        

ASSETS

    

Current Assets:

    

Cash and cash equivalents

   $ 805      $ 818   

Accounts receivable, less allowance for doubtful accounts of $4,485 and $4,737 at June 30, 2016 and December 31, 2015, respectively

     16,953        14,206   

Inventory

     2,096        1,916   

Other current assets

     1,207        861   

Deferred income taxes

     2,743        2,743   
  

 

 

   

 

 

 

Total Current Assets

     23,804        20,544   

Medical equipment held for sale or rental

     1,524        2,277   

Medical equipment in rental service, net of accumulated depreciation

     29,805        27,837   

Property & equipment, net of accumulated depreciation

     2,236        2,370   

Intangible assets, net

     31,855        31,534   

Deferred income taxes

     10,821        11,502   

Other assets

     222        251   
  

 

 

   

 

 

 

Total Assets

   $ 100,267      $ 96,315   
  

 

 

   

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

    

Current Liabilities:

    

Accounts payable

   $ 5,346      $ 6,586   

Current portion of long-term debt

     5,939        5,060   

Other current liabilities

     2,560        3,641   
  

 

 

   

 

 

 

Total Current Liabilities

     13,845        15,287   

Long-term debt, net of current portion

     33,482        29,750   
  

 

 

   

 

 

 

Total Liabilities

   $ 47,327      $ 45,037   
  

 

 

   

 

 

 

Stockholders’ Equity:

    

Preferred stock, $.0001 par value: authorized 1,000,000 shares; none issued

     —          —     

Common stock, $.0001 par value: authorized 200,000,000 shares; issued and outstanding 22,821,647 and 22,623,987, respectively, as of June 30, 2016 and 22,739,550 and 22,541,890, respectively, as of December 31, 2015

     2        2   

Additional paid-in capital

     91,681        91,238   

Retained deficit

     (38,743     (39,962
  

 

 

   

 

 

 

Total Stockholders’ Equity

     52,940        51,278   
  

 

 

   

 

 

 

Total Liabilities and Stockholders’ Equity

   $ 100,267      $ 96,315   
  

 

 

   

 

 

 

 

Page 7 of 10


INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

     Three Months Ended     Six Months Ended  

(in thousands, except share and per share data)

   June 30     June 30  
     2016     2015     2016     2015  

Net revenues:

        

Rentals

   $ 17,185      $ 15,616      $ 34,423      $ 30,755   

Product Sales

     1,881        1,554        3,687        3,140   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net revenues

     19,066        17,170        38,110        33,895   

Cost of revenues:

        

Cost of revenues — Product, service and supply costs

     4,789        3,656        8,295        6,671   

Cost of revenues — Pump depreciation and disposals

     2,191        1,660        4,422        3,281   
  

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit

     12,086        11,854        25,393        23,943   
  

 

 

   

 

 

   

 

 

   

 

 

 

Selling, general and administrative expenses:

        

Provision for doubtful accounts

     1,067        1,143        2,814        2,337   

Amortization of intangibles

     922        713        1,834        1,344   

Selling and marketing

     2,324        2,687        5,139        5,424   

General and administrative

     6,392        5,994        13,061        11,969   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total selling, general and administrative

     10,705        10,537        22,848        21,074   
  

 

 

   

 

 

   

 

 

   

 

 

 

Operating income

     1,381        1,317        2,545        2,869   

Other income (expense):

        

Interest expense

     (327     (387     (632     (1,059

Loss on extinguishment of long term debt

     —          —          —          (1,599

Other income

     7        —          27        19   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total other expense

     (320     (387     (605     (2,639

Income before income taxes

     1,061        930        1,940        230   

Income tax (expense) benefit

     (337     (147     (721     138   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income

   $ 724      $ 783      $ 1,219      $ 368   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income per share:

        

Basic

   $ 0.03      $ 0.03        0.05        0.02   

Diluted

   $ 0.03      $ 0.03        0.05        0.02   

Weighted average shares outstanding:

        

Basic

     22,620,386        22,381,487        22,584,462        22,345,309   

Diluted

     23,109,870        22,824,965        23,069,900        22,743,948   

 

Page 8 of 10


INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

     Six Months Ended  
     June 30  
(in thousands)    2016     2015  
    

NET CASH PROVIDED BY OPERATING ACTIVITIES

   $ 1,869      $ 3,787   
  

 

 

   

 

 

 

INVESTING ACTIVITIES

    

Acquisition of business

     —          (3,786

Purchase of medical equipment and property

     (7,187     (9,474

Proceeds from sale of medical equipment and property

     1,827        1,876   
  

 

 

   

 

 

 

NET CASH USED IN INVESTING ACTIVITIES

     (5,360     (11,384
  

 

 

   

 

 

 

FINANCING ACTIVITIES

    

Principal payments on revolving credit facility, term loans and capital lease obligations

     (29,190     (43,586

Cash proceeds from revolving credit facility

     32,575        51,546   

Debt issuance costs

     —          (157

Common stock repurchased to satisfy statutory withholding on employee stock based compensation plans

     (33     (48

Cash proceeds from stock plans

     126        118   
  

 

 

   

 

 

 

NET CASH PROVIDED BY FINANCING ACTIVITIES

     3,478        7,873   
  

 

 

   

 

 

 

Net change in cash and cash equivalents

     (13     276   

Cash and cash equivalents, beginning of period

     818        515   
  

 

 

   

 

 

 

Cash and cash equivalents, end of period

   $ 805      $ 791   
  

 

 

   

 

 

 

 

Page 9 of 10


INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

NON-GAAP RECONCILIATION

(UNAUDITED)

NET INCOME TO ADJUSTED EBITDA:

 

     Three Months Ended     Six Months Ended  
     June 30,     June 30,  

(in thousands)

   2016     2015     2016     2015  

Net income

   $ 724      $ 783      $ 1,219      $ 368   

Adjustments:

        

Interest expense

     327        387        632        1,059   

Income tax expense (benefit)

     337        147        721        (138

Depreciation

     1,730        1,229        3,373        2,332   

Amortization

     922        713        1,834        1,344   
  

 

 

   

 

 

   

 

 

   

 

 

 

EBITDA

   $ 4,040      $ 3,259      $ 7,779      $ 4,965   

Stock compensation

     137        330        350        617   

Loss on early extinguishment of long term debt

     —          —          —          1,599   

Severance

     75        —          75        202   

Strategic alternatives/transition costs

     95        351        195        404   
  

 

 

   

 

 

   

 

 

   

 

 

 

EBITDA - Adjusted

   $ 4,347      $ 3,940      $ 8,399      $ 7,787   
  

 

 

   

 

 

   

 

 

   

 

 

 
OPERATING INCOME TO ADJUSTED NET INCOME:         
     Three Months Ended     Six Months Ended  
     June 30,     June 30,  

(in thousands)

   2016     2015     2016     2015  

Operating income

   $ 1,381      $ 1,317      $ 2,545      $ 2,869   

Adjustments:

        

Severenace

     75        —          75        202   

Strategic altneratives/transition costs

     95        351        195        404   

Interest expense

     (327     (387     (632     (1,059

Other income

     7        —          27        19   
  

 

 

   

 

 

   

 

 

   

 

 

 

Income before income taxes - adjusted

   $ 1,231      $ 1,281      $ 2,210      $ 2,435   

Income tax expense

     391        202        822        675   
  

 

 

   

 

 

   

 

 

   

 

 

 

NET INCOME - adjusted

   $ 840      $ 1,079      $ 1,388      $ 1,760   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income per share:

        

Basic

   $ 0.04      $ 0.05      $ 0.06      $ 0.08   

Diluted

   $ 0.04      $ 0.05      $ 0.06      $ 0.08   

Weighted average shares outstanding:

        

Basic

     22,620,386        22,381,487        22,584,462        22,345,309   

Diluted

     23,109,870        22,824,965        23,069,900        22,743,948   

 

Page 10 of 10